The Food & Drug Administration issued new guidlines for medical device clinical trials it says can speed the process.
Companies looking to get medical devices to market might want to brush up on their probability theory, after the Food & Drug Administration issued new guidelines for statistical method it says can speed clinical trials.
The FDA said medical device makers can use Bayesian statistical methods to design and analyze clinical trials. Bayesian probability applies an algorithm allowing companies to combine data from previous trials with current trial data. That, in turn, could provide "sufficient justification for smaller or shorter clinical studies," according to a press release.
The federal watchdog agency said it has "substantial experience" in used the method in clinical trials and has cleared "a number" of medical devices from companies that used the method in clinical trials supporting their applications.
The Centers for Medicare and Medicaid Services are also considering the use of Bayesian probability in making coverage decisions, when reviewing trial results or technology assessments, according to the press release.
Warren Watson, a 30-year Medtronic Inc. employee with family connections to founder Earl Bakken, is...
Quidel Corp. wins Food & Drug Administration 510(k) clearance for its chorionic gonadotropin-...
Ann Arbor, Mich.-based HistoSonics Inc. snags former Food & Drug Administration commissioner Dr....
The Food & Drug Administration releases a list of the medical devices it granted 510(k) clearance...
A federal grand jury indicts former Spectranetics CEO John Schulte, two other executives and a...